Skip to content

Press Release Details

Seres' news, events and other information can be found throughout the pages below.

Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering

Jun 25, 2015 at 8:00 PM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 25, 2015-- Seres Therapeutics, Inc. today announced the pricing of its initial public offering of 7,430,555 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Seres Therapeutics. In addition, Seres Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,114,583 shares of common stock from the company at the public offering price. The company's shares are expected to begin trading on The NASDAQ Global Select Market on June 26, 2015 under the ticker symbol “MCRB”.

Goldman, Sachs & Co. and BofA Merrill Lynch are acting as joint book-running managers for the offering, and Leerink Partners and Canaccord Genuity Inc. are acting as lead managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 25, 2015. This offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained by contacting Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com or BofA Merrill Lynch, by mail at 222 Broadway, New York, New York 10038, Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Source: Seres Therapeutics, Inc.

Investor Relations
Stern Investor Relations Inc.
Beth DelGiacco, 212-362-1200
Beth@sternir.com